Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma

NCT00678327 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT00678327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00678327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial to Assess Response Adapted Therapy Using FDG-PET Imaging in Patients With Newly Diagnosed, Advanced Hodgkin Lymphoma
Lead sponsor
University College, London
Phase
Phase 3
Overall status
Completed
Start date
August 29, 2008
Completion date
May 1, 2024
Enrollment
1,202 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma